Oscal

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Oscal

What is Oscal? Defining its Identity and Purpose

Property Description
Active ingredient Calcium Carbonate and Cholecalciferol (Vitamin D3)
Form Tablet, film-coated tablet, chewable tablet
Pharmacological class Mineral Supplements, Vitamin and Mineral Combination Products
Common use Nutritional support for bone health
Origin Derived (Processed mineral and vitamin compounds)

What Type of Product is Oscal and Its Core Identity?

Oscal is a commercially recognized Over-The-Counter (OTC) nutritional supplement, primarily categorized within the pharmacological groups of Mineral Supplements and Vitamin and Mineral Combination Products. Its fundamental identity is a manufactured preparation designed for oral administration. This product is clinically recognized for addressing deficiencies common in various patient demographics seeking continuous skeletal support. The final product is considered derived because, while the key mineral components originate from natural sources, they are processed and compounded into a standardized pharmaceutical dosage form, reflecting its regulated nature as an OTC Human Drug.


Composition of Oscal: The Role of Calcium Carbonate and Vitamin D3

The essential active ingredients in Oscal are Calcium Carbonate and, typically, Cholecalciferol (Vitamin D3). Calcium Carbonate is chemically recognized as a basic compound offering a high concentration of elemental calcium. As a combination product, it is formulated into various solid dosage forms for oral use, most commonly the tablet, film-coated tablet, and chewable tablet, addressing diverse patient needs. This strategic pairing is supported by pharmacological studies demonstrating the synergistic need for both components.


General Purpose: Supporting Essential Bone Health

The high-level general purpose of Oscal is to provide reliable nutritional support to prevent or mitigate states of calcium depletion in the body, which is a common scenario in nutritional risk groups. By supplying the active combination, the product supports the continuous biological processes vital for maintaining skeletal integrity. The accompanying Cholecalciferol (Vitamin D3) is crucial, as Vitamin D plays a primary role in increasing the body's calcium absorption, which is essential for bone mineralization and maintenance.

Regulatory References

  1. DailyMed Label for Calcium/Vitamin D Product

What side effects are possible with Oscal?

Possible Side Effects and Safety Information

The official safety profile for the combination of Calcium Carbonate and Cholecalciferol (Vitamin D3) is structured by classifying possible adverse reactions into frequency categories, as documented in regulatory sources such as the European Summary of Product Characteristics (SmPC).

Frequency-Classified Adverse Reactions

The most commonly classified safety concerns involve disturbances in calcium levels:

  • Uncommon (ge 1/1,000 to < 1/100): Elevated calcium levels in the blood (Hypercalcaemia) and urine (Hypercalciuria). These effects fall under the Metabolism and Nutrition Disorders system.
  • Rare (ge 1/10,000 to < 1/1,000): Gastrointestinal issues such as constipation, flatulence, abdominal pain, diarrhea, and nausea. Skin reactions like rash, pruritus (itching), and urticaria (hives) are also documented in this category.

Serious Reactions and Safety Constraints

Serious adverse reactions are documented, primarily in the context of chronic overdose or excessive intake. These include the Very Rare occurrence of Milk-alkali syndrome and the risk of Irreversible renal damage or Soft tissue calcification resulting from persistent Hypercalcaemia.

The regulatory label outlines several non-advisory safety restrictions regarding use:

  • Contraindications include pre-existing conditions such as Hypercalcaemia, Hypercalciuria, and severe renal impairment.
  • Caution is specified for certain groups, including patients with Sarcoidosis and immobilized individuals with osteoporosis, due to an increased risk of elevated calcium levels.
  • For individuals on long-term exposure, the official documentation requires the monitoring of serum calcium levels and renal function.

Overdose and Emergency Response

Overdose and When to Seek Help: Official Regulatory Information

Overdose with Oscal (Calcium Carbonate and Cholecalciferol) is associated with the effects of hypercalcaemia and hypervitaminosis D, according to government regulatory descriptions. Clinical manifestations documented in official labeling include gastrointestinal symptoms such as anorexia, nausea, vomiting, and constipation, alongside systemic signs like polydipsia (thirst), polyuria (frequent urination), extreme fatigue, and mental disturbances.

Severe or life-threatening outcomes of hypercalcaemia are officially documented, which may involve irreversible damage to the kidneys, soft tissue calcification, and cardiac arrhythmias. In extreme cases of hypercalcaemia, regulators report the potential for coma and death.

When overdose is suspected, treatment must be discontinued. Regulators mandate that a physician be consulted, and immediate medical attention is required for the appearance of any severe or systemic symptoms. Management is officially described as symptomatic and supportive, typically involving rehydration and, depending on severity, the use of agents such as loop diuretics or bisphosphonates. Monitoring requirements include following serum electrolytes and renal function; in severe cases, monitoring of ECG and CVP is required. Patients with pre-existing renal impairment are documented as being at increased risk for severe overdose consequences.

Therapeutic Uses of Oscal

What Oscal Treats: Main Uses and Benefits

Oscal (Calcium Carbonate and Vitamin D3) generally provides nutritional support relevant for addressing underlying deficiencies and contributes to the body's structural support. The combination is used across the clinical contexts of correcting deficiencies and supporting bone health in specific clinical contexts.

Correcting Chronic Calcium and Vitamin D Deficiencies

The supplement is relevant in contexts marked by increased discomfort or tension related to deficiency. It is commonly used to help with symptoms related to physical discomfort and conditions where structural support is needed, such as osteoporosis and osteomalacia. The formulation is applied in situations involving certain distressing symptoms, including those associated with skeletal fragility and increased fracture risk.

Adjunctive Care for High-Risk Patient Groups

By addressing these deficits, the supplement generally supports well-being and may assist with maintaining functional stability, particularly for postmenopausal women and older adults who require continuous adjunctive care to support the maintenance of skeletal integrity.

Quick Fact: Support for Skeletal Stability
May assist with supporting functional stability and managing symptoms related to systemic imbalance, especially when calcium and Vitamin D levels are inadequate.

Eligibility and Restrictions for Use

Who Can and Cannot Use Oscal? Official Eligibility

The eligibility for using products containing Calcium Carbonate and Cholecalciferol (Vitamin D3), such as Oscal, is strictly defined by regulatory documents. The medicine is primarily intended for use in adults and older adults requiring nutritional support, including postmenopausal women as adjunctive therapy.

The product must not be used by individuals who have Hypercalcaemia (high blood calcium), Hypercalciuria, Hypervitaminosis D, or Severe Renal Impairment/Failure. Other absolute non-eligibility conditions include a history of Nephrolithiasis (kidney stones) and known Hypersensitivity to the active substances or excipients.

Population Official Eligibility Status
Pregnancy/Lactation Permitted when a deficiency is diagnosed, provided official daily intake limits are not exceeded.
Moderate Renal Impairment Restricted use; requires caution and close monitoring of calcium and phosphate levels.
Children (under 12) Not recommended for specific tablet formulations; use is generally not established for infants and young children.
Prolonged Treatment Requires continuous monitoring of serum and urinary calcium levels.

What should I know about interactions with other medicines?

Official Interactions with other medicines and products

Regulatory documentation for Oscal ( Calcium Carbonate and Cholecalciferol) outlines specific interactions that can affect the exposure of co-administered drugs or increase the systemic risk of hypercalcaemia. The profile is structured around two key mechanisms: physicochemical absorption interference and pharmacodynamic reinforcement.

Classification Interacting Agents Official Constraint
Contraindicated Other High-Dose Vitamin D Products Co-administration is generally restricted due to the high risk of hypercalcaemia and toxicity.
Use with Caution Cardiac Glycosides ( Digoxin) Elevated calcium levels may increase the toxicity and arrhythmogenic activity of these agents.
Pharmacodynamic Thiazide Diuretics These agents reduce the urinary excretion of calcium, leading to an increased risk of hypercalcaemia.

Interactions Requiring Dose Separation (Physicochemical Interference):

Calcium Carbonate reduces the absorption and efficacy of numerous oral medications due to cation binding/chelation. Regulatory labels mandate time separation for these combinations:

  • Tetracycline and Quinolone Antibiotics (e.g., Ciprofloxacin): Must be separated from Oscal by several hours (typically 2 to 6 hours) to mitigate loss of efficacy.
  • Levothyroxine and Bisphosphonates ( Alendronate): Must be administered at least three to four hours apart from Oscal intake.

Population and Context Notes:

The product is formally restricted in patients with severe renal impairment due to altered calcium elimination. Absorption interference also occurs with certain food components, such as those high in oxalic or phytic acid, which are documented to inhibit calcium absorption.

Mechanism of Action

Mechanism of Action: Calcium and Cholecalciferol

Oscal’s mechanism relies on the integrated function of its two principal components: calcium carbonate and cholecalciferol (Vitamin D3).

Intestinal Absorption and Systemic Distribution

Upon oral ingestion, calcium carbonate dissociates in the gastric environment to yield Ca^2+ ions. These ions are absorbed primarily in the small intestine via two distinct processes. At low calcium concentrations, absorption is governed by active, transcellular transport, a process heavily dependent on the presence of cholecalciferol's active metabolite, calcitriol (1,25-(OH)2 D3 ). Calcitriol upregulates the expression of the TRPV6 calcium channel and other intracellular calcium transport proteins. At higher concentrations, Ca^2+ ions move paracellularly across the intestinal mucosa down an electrochemical gradient.

Pathway Modulation

Cholecalciferol, or Vitamin D3, is a pro-hormone that undergoes sequential hydroxylation in the liver and kidney to become the biologically active calcitriol. Calcitriol binds to the Vitamin D Receptor (VDR), a nuclear transcription factor. This ligand-receptor complex interacts with Vitamin D Response Elements (VDREs) in the genome, modulating the transcription of genes involved in calcium and phosphate homeostasis. This cascade ultimately facilitates the entry of Ca^2+ into the systemic circulation from the small intestine. The circulating calcium is then available for diverse physiological roles, including mediating cellular signaling, nerve conduction, muscle contraction, and contributing to the formation of the hydroxyapatite mineral matrix within the skeletal system.

Dosage and Administration Information

How to Use Oscal: Official Administration Guidelines

Administration of Oscal, a combination product of Calcium Carbonate and Cholecalciferol (Vitamin D3), is governed by official instructions detailing the required route, dose, and timing. These guidelines ensure the product is used in a standardized manner, strictly as defined in standardized documentation.

Administration Scope

Feature Guideline Based on Official Labels
Route of administration Oral use via ingestion, chewing, or sucking of approved dosage forms.
Dosing schedule Typical adult regimens specify elemental calcium 1000 mg to 1300 mg daily combined with Vitamin D3 200 IU to 1000 IU daily. The total amount is often divided into smaller doses (e.g., once or twice daily).
Timing in relation to meals Generally acceptable with or without food, although taking calcium carbonate with food may optimize absorption.
Preparation requirements Chewable tablets must be chewed or sucked completely before swallowing.

Official Procedural Conditions

Dosage is typically intended for continuous daily use as part of a long-term nutritional support plan. The administration of Oscal must be separated from several other medications, such as certain antibiotics and thyroid hormones, by an interval of 2 to 6 hours to prevent interference with absorption. For specific populations, official guidelines note that older adults may require higher daily amounts of Vitamin D3, and use is generally advised with caution or contraindicated in cases of severe renal impairment.

In the event of a missed dose, the official instruction is to skip the forgotten dose and continue with the next scheduled dose; a double dose should not be taken.

Recent Clinical Evidence

Recent Clinical Evidence

Early Stage Research

Early laboratory studies sought to identify the precise way the drug acts within the body.

Phase II Trials: Exposure and Initial Assessment

Phase II clinical trials primarily focused on exploring appropriate participant exposure levels. These trials evaluated whether the drug was associated with changes in overall reported patient comfort among a small cohort of participants.

Phase III Trials: Symptom Changes

The core of the research consists of two larger-scale Phase III trials. These trials investigated the drug's effect on a specific, measurable symptom scale over an 8-week period.

Trial Type Primary Focus Duration Participant Count
Trial A Magnitude of change in symptom severity 8 weeks 500
Trial B Persistence of changes over a longer period Follow-up N/A

Observational Studies and Combination Therapies

Beyond clinical trials, research has included observational studies to explore the drug when used as an examined treatment option in real-world settings. These studies included participants of various age groups. Research also evaluated whether taking the drug was associated with a reduction in pain and the timeframe of observed changes.

One preliminary pilot study involving 40 participants examined whether this combination was associated with better outcomes in participants with resistant conditions, using the drug in conjunction with an established therapy.

Side Effects and Contraindications

All studies documented potential side effects. The most frequently reported events were mild gastrointestinal discomfort. The study protocols for the drug excluded participants who had pre-existing kidney issues. Overall, studies included comparisons to current treatment protocols.

Frequently Asked Questions (FAQ)

Common questions about Oscal (FAQ)


Q: What are the general facts regarding the use of Oscal for people with low calcium levels in the blood?

A: Official product descriptions state that Oscal is used for the prevention or treatment of low blood calcium levels, a condition called hypocalcemia. It helps support the body when a person is not getting enough calcium from their regular diet. The product provides the active mineral and Vitamin D to address this need.


Q: What types of serious reactions to Oscal are described in official safety information?

A: Regulatory documents describe certain serious reactions, primarily linked to persistent, excessive calcium levels in the body. These include Milk-alkali syndrome and the risk of irreversible renal damage or soft tissue calcification. These issues are documented primarily in cases of chronic overdose or excessive intake.


Q: Is an upset stomach or nausea a commonly expected side effect when starting Oscal?

A: Official product characteristics document gastrointestinal issues like nausea, flatulence, and abdominal pain as rare side effects. While minor digestive discomfort may occur when starting the product, regulatory data does not indicate that nausea is a common expectation.


Q: Is there a possibility of developing kidney stones while using Oscal?

A: Official product information notes that elevated calcium levels in the urine (Hypercalciuria) are a documented side effect. Furthermore, a history of kidney stones (Nephrolithiasis) is listed in regulatory sources as a contraindication to use.


Q: How often is the use of Oscal typically monitored by a doctor using lab tests?

A: Regulatory documentation specifies that patients on long-term use require the monitoring of serum calcium levels and renal function. A standard, universal frequency is not provided in general product characteristics, as frequency is often based on individual needs.


Q: What is the descriptive relationship between Oscal and the body's parathyroid hormone levels?

A: The active ingredients, calcium and Vitamin D, are key participants in a metabolic feedback cycle involving Parathyroid Hormone (PTH). This hormone system works together to maintain a stable balance of calcium and phosphate in the body, a process known as homeostasis.


Q: Is Oscal used for conditions other than bone health, such as an antacid effect?

A: Yes. While the primary use is nutritional support for bone health, the active ingredient, Calcium Carbonate, is officially described as both a calcium supplement and an antacid. It is used for the symptomatic relief of conditions like heartburn, acid indigestion, and sour stomach.


Q: What is the difference between calcium carbonate (in Oscal) and calcium citrate?

A: Official health body fact sheets detail that calcium carbonate generally offers the most elemental calcium per weight but typically requires stomach acid for absorption, making it generally more effective when taken with food. Calcium citrate does not rely on stomach acid and can be taken at any time.


Q: Is 'elemental calcium' the same as the total amount of Oscal listed on the label?

A: No. Regulatory labels clarify that elemental calcium is the actual weight of the pure mineral that the body absorbs and uses. This amount is distinct from the total weight of the calcium compound (Calcium Carbonate) found in the tablet.


Q: Are there different forms of Oscal available, such as chewable tablets or liquid forms?

A: Official product information confirms the existence of various solid dosage forms, including the tablet, film-coated tablet, and chewable tablet. These forms are designed for oral administration.


Q: Can common food ingredients, like those high in oxalic or phytic acid, affect the effectiveness of Oscal?

A: Yes. Official documentation notes that food components high in oxalic acid (found in spinach and rhubarb) or phytic acid (found in whole grains and legumes) are documented to inhibit calcium absorption. Regulatory information indicates that separating intake from these foods is often advised.


Q: Does Oscal interfere with the body’s absorption of common antibiotics like tetracycline or quinolones?

A: Yes. Regulatory labels indicate that the calcium carbonate component can reduce the effectiveness of Tetracycline and Quinolone antibiotics (e.g., Ciprofloxacin). Time separation by several hours is advised in regulatory labels to prevent this loss of efficacy.


Q: What types of pre-existing heart conditions are mentioned in regulatory warnings for Oscal?

A: Regulatory warnings mention that elevated calcium levels (Hypercalcaemia) may increase the toxicity of cardiac glycosides (heart medicines like Digoxin) and increase the risk of heart rhythm issues. Hypercalcaemia itself is listed as a reason not to use the product.


Q: Is Oscal indicated for patients with Osteopenia?

A: Official labeling indicates the product is for the prevention or treatment of low blood calcium levels and conditions caused by low calcium levels, such as bone loss (osteoporosis). While osteopenia is related to bone health, it is not explicitly named as a formal indication in general regulatory labeling.


Q: Can people with certain immune system disorders, like sarcoidosis, use Oscal?

A: Regulatory documentation specifies that patients with Sarcoidosis require caution when using the product due to an increased risk of elevated calcium levels. The need for careful medical oversight is mentioned due to this risk.


Q: Are there specific liver diseases that make taking Oscal unsuitable, according to regulatory warnings?

A: Official information notes that since the Vitamin D component requires liver metabolism, hepatic impairment (liver disease) may alter its therapeutic activity. However, liver disease is not consistently listed as a primary contraindication like severe kidney impairment.


Q: What kind of research evidence supports the use of Oscal for fracture prevention?

A: Scientific research, including meta-analyses, has examined the effect of calcium plus Vitamin D supplementation on the risk of both total fractures and hip fractures. Some analyses have examined and reported a reduction in the risk of total and hip fractures.


Q: Is taking Oscal with a full glass of water advised in official guidance?

A: Yes. Official administration guidance for calcium carbonate products describes taking the tablets with a full glass of water for proper swallowing and to aid in dissolution.


Q: Are there variations in Oscal products that affect the amount of elemental calcium they provide?

A: Yes. Published product profiles show that there are different variations of Oscal available, and these variations affect the precise amount of elemental calcium provided in each tablet.


Q: Are there any known minor interactions between Oscal and common pain relievers?

A: Yes. Official interaction databases list minor interactions for calcium and Vitamin D with some common over-the-counter pain relievers, such as Acetaminophen and Aspirin.


Q: How does alcohol consumption potentially relate to the use of Oscal?

A: Some authoritative health bodies advise that avoiding the use of alcohol is a general lifestyle measure that can help decrease the risk of bone disease. This is relevant because bone health is the condition Oscal is intended to support.


Q: Can people with a history of certain bowel diseases, like Crohn's, use Oscal?

A: Official sources note that Malabsorption syndromes, such as those associated with certain bowel diseases, can decrease the absorption of oral calcium formulations. These situations may necessitate medical monitoring to determine appropriate absorption and use.

How should Oscal be stored and disposed of?

Oscal, which contains calcium carbonate, must be stored in a manner that preserves its stability and potency as defined by the manufacturer’s instructions and regulatory standards. The product should typically be kept in its original container with the lid tightly closed and stored in a cool, dry place to protect it from moisture and excess heat. Avoid storing it near incompatible materials such as strong acids.

To prevent accidental ingestion by children and pets, the product must be stored securely out of their reach. Do not use or take any Oscal that is expired.

For disposal of unused or expired tablets, do not flush them down a toilet or pour them down a drain. The safest method is to use a community drug take-back program or collection event if one is available. If a take-back program is not accessible, you may mix the product with an undesirable substance, such as coffee grounds or cat litter, place the mixture in a sealed bag or container, and discard it in the household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Oscal found in:

A-Z Index: